IV iron formulations and use in adults
Copyright © 2023 by The American Society of Hematology..
Intravenous iron has become a major component of the therapeutic armamentarium for iron deficiency and iron deficiency anemia. The earliest formulations were associated with unacceptable toxicity. Newer formulations, with complex carbohydrate cores that bind elemental iron more tightly, allow the administration of full therapeutic doses in 15 to 60 minutes. Nonetheless, a folklore of danger, fueled by earlier formulations no longer available, continues to foment caution. Complement-mediated minor infusion reactions, referred to as complement activation-related pseudo-allergy, resolve without therapy. Inappropriate intervention with vasopressors and H1 blockers converts these minor reactions into hemodynamically significant adverse events. Four new formulations, low-molecular-weight iron dextran, ferumoxytol, ferric carboxymaltose, and ferric derisomaltose, all approved for the treatment of iron deficiency in a host of conditions, are now widely used with an excellent safety profile. Herein, the administration, safety, indications, and management of infusion reactions are discussed. Treatment-emergent hypophosphatemia, a newly recognized side effect for some formulations, is also reviewed. Based on the preponderance of published evidence, intravenous iron should be moved up-front for the treatment of iron deficiency and iron deficiency anemia in those conditions in which oral iron is suboptimal.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2023 |
|---|---|
| Enthalten in: |
Hematology. American Society of Hematology. Education Program - 2023(2023), 1 vom: 08. Dez., Seite 622-629 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Van Doren, Layla [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
14127-53-8 |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 15.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1182/hematology.2023000495 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365577464 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365577464 | ||
| 003 | DE-627 | ||
| 005 | 20240215231946.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/hematology.2023000495 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1294.xml |
| 035 | |a (DE-627)NLM365577464 | ||
| 035 | |a (NLM)38066930 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Van Doren, Layla |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IV iron formulations and use in adults |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 15.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 by The American Society of Hematology. | ||
| 520 | |a Intravenous iron has become a major component of the therapeutic armamentarium for iron deficiency and iron deficiency anemia. The earliest formulations were associated with unacceptable toxicity. Newer formulations, with complex carbohydrate cores that bind elemental iron more tightly, allow the administration of full therapeutic doses in 15 to 60 minutes. Nonetheless, a folklore of danger, fueled by earlier formulations no longer available, continues to foment caution. Complement-mediated minor infusion reactions, referred to as complement activation-related pseudo-allergy, resolve without therapy. Inappropriate intervention with vasopressors and H1 blockers converts these minor reactions into hemodynamically significant adverse events. Four new formulations, low-molecular-weight iron dextran, ferumoxytol, ferric carboxymaltose, and ferric derisomaltose, all approved for the treatment of iron deficiency in a host of conditions, are now widely used with an excellent safety profile. Herein, the administration, safety, indications, and management of infusion reactions are discussed. Treatment-emergent hypophosphatemia, a newly recognized side effect for some formulations, is also reviewed. Based on the preponderance of published evidence, intravenous iron should be moved up-front for the treatment of iron deficiency and iron deficiency anemia in those conditions in which oral iron is suboptimal | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a ferryl iron |2 NLM | |
| 650 | 7 | |a 14127-53-8 |2 NLM | |
| 650 | 7 | |a Iron |2 NLM | |
| 650 | 7 | |a E1UOL152H7 |2 NLM | |
| 650 | 7 | |a Ferrosoferric Oxide |2 NLM | |
| 650 | 7 | |a XM0M87F357 |2 NLM | |
| 700 | 1 | |a Auerbach, Michael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hematology. American Society of Hematology. Education Program |d 2000 |g 2023(2023), 1 vom: 08. Dez., Seite 622-629 |w (DE-627)NLM115942556 |x 1520-4383 |7 nnns |
| 773 | 1 | 8 | |g volume:2023 |g year:2023 |g number:1 |g day:08 |g month:12 |g pages:622-629 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/hematology.2023000495 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2023 |j 2023 |e 1 |b 08 |c 12 |h 622-629 | ||